Click on the image to view the entire poster.
| ACTHIV® ChangeMakers 2024-25: Clinicians Applying an Adaptive Leadership Framework to Improve HIV Care |
ACTHIV® ChangeMakers 2024-25: Optimizing Bicillin Administration for Syphilis Treatment in the Carceral Setting |
Analyzing Knowledge Status and HIV Linkage to Care: Insights From America’s HIV Epidemic Analysis Dashboard (AHEAD) National Database |
 |
 |
 |
| Monitoring for HBV Reactivation in PWH Following Antiretroviral Switch to Cabotegravir/Rilpivirine | Premier Platinum Program (PPP): Harmonizing the syndemic of people aging with HIV | Weight Concerns and Management in People with HIV (PWH) and without HIV (PWoH): A Qualitative Exploration of Healthcare Provider Experiences |
 |
 |
 |
| A Mixed-Methods Study of Rapid ART in People Living with Advanced HIV in the Rio Grande Valley | INCREASE PREP UTILIZATION, AWARENESS,AND EDUCATION AMONG UNDERSERVEDPOPULATIONS IN DALLAS COUNTY | Double IRIS in HIV/AIDS: The Intersection of Immune Reconstitution and Health Disparities |
 |
 |
 |
| HIGH LEVELS OF TREATMENT SUCCESS SEEN WITH COMBINED USE OF TESAMORELIN AND GLP1-RAs IN PEOPLE WITH HIV | The Impact of a Fellow-Led Educational Presentation on Trainees’ Knowledge and Interest in HIV Medicine and/or Infectious Diseases |
At the Heart of Healing: Social Work’s Impact in Integrated HIV Care Model |
 |
 |
 |
| Lessons from Having a Dedicated Medical Assistant for Implementing Long-Acting ART at a Hospital-Based Clinic | Pregnancy Related Outcomes Between INSTI and Non-INSTI ART Regimens in an Urban Hospital Ryan White Clinic | Examining Low Level Viremia Based on Body Mass Index in Injectable Cabotegravir/Rilpivirine |
 |
 |
 |
| Anal Cancer Screening in a Population of PLWH in an Urban Underserved FQHC Residency Clinic Network: Gaps and Proposal for Increasing Screening | An enabling technology-based specialty pharmaceutical company with focus on long-acting injectables (LAIs) | Using Contingency Management to Increase Uptake of Long-Acting Injectable PrEP in People Who Use Drugs: Harm Reduction & Street Medicine in Detroit |
 |
 |
 |
| “Harm Reduction Angels”: Linking Veterans Who Inject Drugs to Key Resources |
Evaluating Impact of a Pharmacist-Led HIV PrEP Clinic for Veterans in Outpatient Substance Use Treatment |
The Case for Care Coordination through the Lens of Adaptive Leadership |
 |
 |
 |
| ACTHIV ChangeMakers: An Artistic Expression of Wellness in the Ponce Clinic Community |
Evaluating Impact of a Pharmacist-Led HIV PrEP Clinic for Veterans in Outpatient Substance Use Treatment |
Language matters when communicating about HIV. Survey of 100 PLH at the monthly updates hosted by the San Diego HIV Consortium (SDHIVConsortium.org) |
 |
 |
 |
| Grassroots Initiative to Address Mental Health Needs Among People Living with HIV (PLH) in San Diego, CA, USA | Trends in HIV-1 Drug Resistance in the United States: 2019-2024 | Overlap of Pre-exposure Prophylaxis (PrEP) Landscape and Substance Use in the United States (US) |
 |
 |
 |
| High Real-World Adherence With Long-Acting Cabotegravir Plus Rilpivirine (CAB+RPV LA) Among People With HIV (PWH) in the United States (US) | PILLAR Month 12 Clinical Results: Zero HIV Acquisition and High Persistence With CAB LA for PrEP | Change in Healthcare Professional’s Identification, Counseling, and Adherence With Black Women for Long-Acting Cabotegravir (CAB LA) for PrEP Across Women’s Health, Primary Care, and Infectious Diseases Sites: Findings From the EBONI Study |
 |
 |
 |
| PAIRED – PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub-analysis of people with HIV switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States (US) | Interim demographic, clinical characteristics, and effectiveness in the REGAL cohort: a REtrospective real-world study of the effectiveness and tolerability of the antiretroviral treatment reGimens DTG/3TC compAred to BIC/FTC/TAF in older persons Living with HIV | Treatment-Emergent Integrase Strand Transfer Inhibitor (INSTI) Resistance-Associated Mutations Among People With HIV-1 Treated With Dolutegravir (DTG) + Lamivudine (3TC) With Pre-existing M184V/I From Real-world and Interventional Studies |
 |
 |
 |
| Perceived Impact of an Electronic Patient-Reported Outcomes Platform (MyPRO) on Patient-Provider Interactions Among Women Living With and Without HIV in a Community Health Clinic Serving Racialized Women in Toronto, Canada | Enhanced Patient Experiences After 12 Months Switch to Cabotegravir and Rilpivirine Long-Acting Therapy: High Treatment Satisfaction, Strong Preference, and Reduced Treatment-Related Challenges Across Gender, Race, and Age in the Real-world BEYOND Study | High and Consistent Virologic Suppression Rates With Similar Adherence Were Observed Across Demographic Subgroups (Gender, Age, Race, BMI) Following 12 Months Switch of Cabotegravir and Rilpivirine Long-Acting Therapy in the Real-world BEYOND Study |
 |
 |
 |